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Introduction
Positron emission tomography (PET) has become 
the hallmark of nuclear medicine attributed to its 
high sensitivity, better spatial resolution and absolute 
quantification. This is due to ability of PET radionuclides 
to incorporate into biological molecules with subtle 
disruption of biological process of disease. Since its 
introduction in 1999, PET/CT hybrid imaging (or 
PET/MRI in recent years) has become standard of 
care primarily in oncology and also in cardiology and 
neurology (Alavi et al., 2004; Liu et al., 2013). In fact 
successful marriage between PET (functional) and CT 
or MRI (anatomical) modalities is the sentinel reason for 
this robust and accelerated application in clinical arena 
and its demand worldwide (Gambhir et al., 2001). A 
large number of Fluorine-18 (18F), Carbon-11 (11C) and 
Gallium-68 (68Ga) labeled radiopharmaceuticals are being 
used for various clinical indications. But 18F labeled 
fluorodeoxyglucose (18FDG) is the most commonly used 
PET radiopharmaceutical around the globe (Schmor, 
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Abstract
 Positron emission tomography (PET) as the functional component of current hybrid imaging (like PET/
CT or PET/MRI) seems to dominate the horizon of medical imaging in coming decades. 18Flourodeoxyglucose 
(18FDG) is the most commonly used probe in oncology and also in cardiology and neurology around the globe. 
However, the major capital cost and exorbitant running expenditure of low to medium energy cyclotrons (about 
20 MeV) and radiochemistry units are the seminal reasons of low number of cyclotrons but mushroom growth 
pattern of PET scanners. This fact and longer half-life of 18F (110 minutes) have paved the path of a centralized 
model in which 18FDG is produced by commercial PET radiopharmacies and the finished product (multi-dose 
vial with tungsten shielding) is dispensed to customers having only PET scanners. This indeed reduced the cost 
but has limitations of dependence upon timely arrival of daily shipments as delay caused by any reason results 
in cancellation or rescheduling of the PET procedures. In recent years, industry and academia have taken a step 
forward by producing low energy, table top cyclotrons with compact and automated radiochemistry units (Lab-
on-Chip). This decentralized strategy enables the users to produce on-demand doses of PET probe themselves 
at reasonably low cost using an automated and user-friendly technology. This technological development would 
indeed provide a real impetus to the availability of complete set up of PET based molecular imaging at an 
affordable cost to the developing countries. 
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2011) and some have also recommended it role in cancer 
screening (Ghotbi et al., 2007) In this technical note we 
will focus upon pharmacokinetics of 18FDG, its synthesis, 
logistic pertinent to its supply and future overview.
18Flourodeoxyglucose (18FDG)
In 1976 at Brookhaven National Laboratory, Tatsuo 
Ido and Wolf Al and their team successfully produced 
18FDG and this step had provided a real impetus to PET 
imaging (Ido and Wolf, 1978). Dr. Abbas Alavi was the 
first nuclear physician who injected 18FDG in two normal 
volunteers for brain imaging (Alavi, 2013). 
18FDG is a radiolabeled analog of glucose, in which 
the hydroxyl group on the 2-carbon of a glucose molecule 
is replaced by a fluoride atom. It competes with glucose 
for active transport from blood to cells by various type 
of specific facilitative glucose transport proteins (GLUT). 
Within the cell it is phosphorylated by hexokinase to FDG-
6-phosphase (FDG-6-P) as the first step toward glycolysis. 
However, FDG-6-P cannot undergo further metabolism as 
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it is not a substrate for further glycolytic pathways and 
effectively trapped intracellularly (Gallagher et al., 1978). 
This metabolic trapping of 18FDG is the seminal reason 
of in vivo imaging and assessment of metabolic function. 
Malignant tumors have high avidity for glucose and 
enhanced glycolysis and have over-expressions of GLUT, 
especially GLUT1 and GLUT3. Importantly inflammatory 
tissues also have high expressions of GLUT1 (Mochizuki 
et al., 2001) leading to a false positive findings and 
diagnostic dilemma in clinical PET imaging (Chung et 
al., 2004). The degree of 18FDG uptake correlates with 
expressions of GLUT1 which is likewise related to tumor 
grade in many tumor types (Tateishi et al., 2006) but 
not necessary all malignancies (Avril, 2004). Glucose 
metabolism in heart muscle, fat and skeletal muscle is 
mediated by GLUT4 which is insulin-dependent. It is 
imperative to be cognizant of expression and up-regulation 
of various GLUTs and activity level of hexokinase to 
understand basis of physiological, pathological and 
nuisance uptake of 18FDG (Brown et al., 2002).
Biodistribution of 18FDG in human body depends 
upon pattern of glucose metabolism in various organs. 
High 18FDG uptake is seen in brain and urinary tract. 
Since 18FDG unlike glucose is not reabsorbed by renal 
tubules, approximately 20% of the administered dose 
is excreted unchanged within the first 2 hours after 
administration (Thomson, 2003). Areas of consistent 
uptake of intermediate intensity are liver, spleen, thyroid 
and bone marrow (in patients without drugs or conditions 
that would potentially stimulate bone marrow activity). 
Other areas which may show physiological uptake are 
salivary glands, lymphoid tissues in the head and neck, 
thymus (especially in children), lactating breast and areola, 
uterus (during menses), GI tract, and skeletal and smooth 
muscle (Delbeke et al., 2006). Visualization on myocardial 
18FDG uptake in oncological imaging exhibits a large 
degree of unexplained intra- and inter-subject variability 
most likely the result of varying levels of insulin present 
or some specific cardiac disorders (Fukuchi et al., 2007).
Synthesis of 18FDG
18FDG synthesis is a multi-stage process that begins 
with production of radioactive 18F (a positron emitting 
radionuclide) in a cyclotron. Radioactive 18F can be 
produced in cyclotron by either electrophilic 18Fluorine 
(18F
2
) or nucleophilic 18Fluoride (18F-) followed by two 
different processes to synthesize 18FDG as electrophilic 
fluorination and nucleophilic substitution respectively. 
18FDG at Brookhaven National Laboratory in 1976 was 
synthesized by electrophilic fluorination using neon gas 
target with 0.1-1% of fluorine gas via 20Ne (d,α) 18FDG 
reaction (Fowler and Ido, 2002). The major limitations 
of this approach are low yield (8%), long synthesis time 
(2 hour) and incorporation of only 50% of 18FDG into 
precursor molecule (Triacetylglucal) (Casella et al., 1980; 
Fowler and Ido, 2002). In nucleophilic fluorination, 18F- 
is produced by bombarding 18O enriched water (18O(p, 
n)18F-) followed by substitution reaction in precursor 
Mannose Triflate in presence of a catalyst Kryptofix222TM 
and acetonitrile as solvent (Hamacher et al., 1986). This 
method was introduced by Hamacher et al (1986) and has 
a consistent yield of over 65% and shorter synthesis time 
of 50 min (www-pub.iaea.org/MTCD/publications)1. Due 
to these facts, nucleophilic method using 18O(p, n)18F is 
the current method of choice for 18FDG synthesis.
Cyclotrons
The robust growth of PET imaging over the last two 
decades has been associated with exemplary growth 
in cyclotron industry as these particle accelerators 
provide positron emitting isotopes. It was E Lawrence 
who invented the first cyclotron in 1930 (Lawrence and 
Edlefson, 1930) and in last 80 years phenomenal growth 
has been observed in design and functioning of cyclotrons. 
Currently various types of cyclotrons are available 
like negative ion accelerating cyclotron, positive ion 
accelerating cyclotron, superconducting cyclotron, low 
energy linear accelerator and electrostatic accelerators 
(Schmor, 2011). However, due to higher yield and lesser 
running cost, negative ion cyclotrons are commonly used 
in health sector. The cyclotrons can also be classified 
according to proton energies: (a) <20 MeV cyclotrons 
are primarily used for production of positron emitting 
radionuclide; (b) cyclotrons with 20-35 MeV which can 
produce gamma emitting isotope as well as positron 
emitting radionuclide and (c) cyclotrons >35 MeV proton 
energies which are used to produce isotopes for therapy 
purposes (Schmor, 2011). According to an IAEA 2006 
report, about 50% of cyclotrons worldwide are less than 20 
MeV and about 75% are being used for 18FDG production 
(IAEA Tech. Rep. IAEA-DCRP, 2006).
Centralized Production of 18FDG other PET 
Probes 
Short half-life of positron emitting radionuclide (like 
15Oxygen=2 minute, 11Carbon=20 minutes, 13Nitrogen=10 
minutes, etc.) demands an onsite cyclotron facility. But 
capital cost, infrastructure and high ongoing personnel 
and operating costs of these cyclotrons are the major 
reasons of their non-existence in every PET/CT facility. 
However, longer half-life of 18FDG (110 minute) allows 
time for complex synthesis or delayed imaging and it can 
be transported to other PET facilities placed at significant 
distances (Schlyer, 2004). In this centralized model, 
18FDG is produced by commercial PET radiopharmacies 
and dispensed the finished product (multi-dose vial with 
tungsten shielding) to customers having PET imaging 
services by special vehicle or by air. This model has been 
successfully practiced in many countries as spreading the 
18FDG production cost over many customers has made 
it affordable and accessible to these users. A batch of 
18FDG can be increased by simply changing the amount 
of the radioactive isotope at the beginning of synthesis, 
a function of the bombardment time in the cyclotron 
with no change in the synthesis, purification, and quality 
control (QC) steps. However, the disadvantage of this 
centralized model is total dependence on timely arrival 
of daily shipments as delays due to any reason results 
in rescheduling or cancellation of procedures and 
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inconvenience to patients and imaging service providers. 
Future Prospects (Decentralized Production 
of 18FDG and other PET Probes) 
Continuous research and recent developments in PET 
radiopharmacy has opened a new vista of decentralized 
approach. This enables the users to produce on-demand 
doses of PET probe themselves at a reasonably low cost 
using an automated and user friendly technology. This 
concept has been materialized by Advanced Biomarker 
Technology (ABT Molecular Imaging, Inc) which has 
introduced a 7.5 MeV, small table-top cyclotron to produce 
single patient doses of 18F (and 11C in future). This system 
is interfaced with a compact, self-shielded and automated 
radiochemistry module dispensing 18FDG dose on demand 
(http://advancebiomarker.com). To excel decentralized 
production, new technologies and automation are needed 
that simplify tracer production, reduce cost, size and 
complexity of equipment required, and eliminate the 
need for highly skilled radiochemists in routine tracer 
production. Already marketed kit-based radiosynthesizers 
and upcoming microfluidic technologies (Lab-on-Chip) 
will enhance the benefits of decentralized production of 
PET probes on demand by users themselves (Schmor, 
2011). This technological development would indeed 
provide a real impetus to the availability of full-fledged 
PET based molecular imaging at an affordable cost to the 
developing countries.
18FDG is the most commonly used PET probe 
around the globe with countable production facilities 
nourishing a large number only-PET imaging facilities 
(centralized approach). However, recent developments 
on technological frontiers have produced low energy, 
table-top and small foot print cyclotrons with compact and 
fully automated radiochemistry module with microfluidic 
technology (Lab-on Chip). This decentralized approach 
would enable the users to produce on-demand dose of 
PET probes by themselves at reasonably low cost by 
acquiring these compact, automated, relatively low cost 
and user friendly units.
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